Conference Reports

ESCMID Conference on Corona Virus Disease (ECCVID)

virtual
23 September 2020 - 25 September 2020

10th International AIDS Society (IAS) Conference on HIV Science (IAS 2019)

Mexico City, Mexico
21 July 2019 - 24 July 2019

American Thoracic Society 2019 (ATS 2019) International Conference

Dallas, Texas, US
17 May 2019 - 22 May 2019

29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2019)

Amsterdam, The Netherlands
13 April 2019 - 16 April 2019

22nd International AIDS Conference (AIDS 2018)

Amsterdam, the Netherlands
23 July 2018 - 27 July 2018

American Thoracic Society International Conference 2018 (ATS 2018)

San Diego, California, US
18 May 2018 - 23 May 2018
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Infectious Diseases - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 5 days ago
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
2 days ago
Nocturia is a risk factor for mortality, according to the results of the Nagahama Study, which boasts of a low incidence of missing data and high representation of the general population.
Audrey Abella, 14 Oct 2020
Despite a 90-percent cure rate after first treatment for children with acute lymphoblastic leukaemia (ALL), approximately 10–15 percent of patients with paediatric ALL will experience relapse. [Expert Rev Anticancer Ther 2017;17:725-736] A recent webinar on the current landscape of ALL highlighted the potential of immunotherapy for paediatric patients with relapsed or refractory ALL, thus providing hope for this high-risk patient group.